Clinical trial
PV-10 Chemoablation of Recurrent Breast Carcinoma
NCT00237354 · Provectus Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00237354 |
|---|---|
| Title | PV-10 Chemoablation of Recurrent Breast Carcinoma |
| Official title | A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma |
| Lead sponsor | Provectus Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | PV-10 (rose bengal disodium 10%) |
| Enrollment | 15 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Oct 12, 2005 |
| Last update posted | Oct 24, 2008 |
| Countries | New Zealand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: